Abstract
By February 2022, European and US agencies recommended use of the BNT162b2 mRNA COVID-19 vaccine (Pfizer–BioNTech) as a primary two-dose series in children aged 5–11 years and as a booster dose in adolescents aged 12–15 years.1–2 Since then, some real-world BNT162b2 vaccine effectiveness data among children and adolescents have generally showed moderate protection against symptomatic infection,3–6 with better protection against COVID-19-associated serious outcomes (emergency department visits and hospitalisations),6–9 especially in the weeks immediately after vaccination.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
